Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Common Equity (2016 - 2025)

Sanofi's Common Equity history spans 11 years, with the latest figure at $83.1 billion for Q4 2025.

  • For Q4 2025, Common Equity changed 0.32% year-over-year to $83.1 billion; the TTM value through Dec 2025 reached $83.1 billion, changed 0.32%, while the annual FY2025 figure was $80.6 billion, 3.87% down from the prior year.
  • Common Equity for Q4 2025 was $83.1 billion at Sanofi, roughly flat from $82.8 billion in the prior quarter.
  • Across five years, Common Equity topped out at $83.1 billion in Q4 2025 and bottomed at $76.3 billion in Q4 2022.
  • The 5-year median for Common Equity is $79.7 billion (2023), against an average of $80.1 billion.
  • The largest annual shift saw Common Equity grew 4.42% in 2021 before it dropped 2.89% in 2022.
  • A 5-year view of Common Equity shows it stood at $78.6 billion in 2021, then fell by 2.89% to $76.3 billion in 2022, then increased by 4.41% to $79.7 billion in 2023, then rose by 3.97% to $82.8 billion in 2024, then rose by 0.32% to $83.1 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Common Equity are $83.1 billion (Q4 2025), $82.8 billion (Q4 2024), and $79.7 billion (Q4 2023).